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Introduction
C onventional randomized clinical trials (RCTs) may not accurately reflect the relative real-world effectiveness of alternative medical treatments in the environment of actual practice. Health services researchers have increasingly utilized retrospective administrative claims databases (RACDs) to make more realistic treatment cost comparisons. While relatively inexpensive and containing information on very large numbers of patients, RACDs typically are unable to provide information on patient illness severity, physician/patient/provider relationships, and clinical outcome. Analyses based on RACDs require methodological care due to possible biases related to nonrandom patient assignment [1] [2] [3] . In large part because of their realworld foundations, RACDs have been the basis for numerous economic analyses comparing different treatment alternatives.
A number of recently published studies employing RACDs have compared treatment costs for depressed patients prescribed tricyclic antidepressants (TCAs), and/or one of the three leading selective serotonin reuptake inhibitors (SSRIs)-fluoxetine, sertraline, and paroxetine [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Although the prevailing evidence suggests that SSRIs are cost-effective treatment alternatives to TCAs, to date the published evidence comparing health care costs among the different SSRIs has not been as consistent.
Since depression is one of the most prevalent mental disorders [18] , carries a substantial economic burden [19] , and is effectively treated with SSRIs [20] [21] [22] [23] , it is important to continue to assess the relative cost-effectiveness of the different SSRIs. Given the mixed results in the literature, it is equally important to critique these studies and clarify how methodological differences can influence results.
Common analysis issues are: the effects of comparing newly approved with more established agents [3, 6] , the sensitivity of results to infrequent high-cost outlier observations (e.g., hospitalization costs) and overfitting [24, 25] , the effects of nonrandom unobserved factors that affect both treatment choice and cost (i.e., patient-providerphysician relationship) [3, 5, 7] , and the robustness and sensitivity of conclusions to alternative statistical procedures and assumptions that may affect the measurement of variability and power to detect a statistical difference [24] .
In this study, we build on our previous research [6] and examine the robustness and sensitivity of direct treatment cost comparisons among fluoxetine, sertraline, and paroxetine using a wide variety of alternative statistical methods. Our analysis is based on 1995 to 1996 RACD from MarketScan TM , a publicly available dataset distributed by MedStat, used in several of the aforementioned studies.
To understand better several important methodological issues inherent in the analysis of RACDs, we begin by reviewing two published articles.
The Sclar et al. Study
Based on nonpublicly available RACD data from a large HMO in the US Pacific Northwest, Sclar et al. [8] compare 12-month direct depression-related health care costs following an index prescription (defined here and throughout as the initial prescription following at least 6 months with no prescription for a depressive disorder) for one of three SSRIs (fluoxetine, paroxetine, or sertraline) between January 1, 1989 and March 31, 1994. They report that, based on their multivariate regression analyses, treatment with paroxetine or sertraline resulted in significantly increased total depression-related health care costs relative to fluoxetine. They attribute the cost differentials to greater titration of sertraline and paroxetine relative to fluoxetine.
During the 5-year (60-month) time interval of this study, fluoxetine was continuously available, whereas sertraline was only available for the last 26 months (from February 1992), and paroxetine the final 15 months (from January 1993) of the study. As a result, many physicians and their HMOs were not able to prescribe sertraline and paroxetine in the beginning of the study period, and may have had inadequate time to gain sufficient experience with paroxetine and sertraline. Moreover, to the extent physicians prescribed the new antidepressants preferentially to those patients refractory to previous treatment, paroxetine and sertraline may have been prescribed disproportionately to patients having more difficult and complex depressive disorders. This phenomenon has been called channeling or allocation bias by Egbert et al. [3] , who documented that three antidepressants newly introduced into the Netherlands from 1994 to 1995 (mirtazapine, sertraline, and venlafaxine) were disproportionately channeled to patients who did not respond satisfactorily to previous pharmacologic treatment. The Sclar et al. [8] study offers some suggestive evidence also supporting this channeling hypothesis. In that study, patients treated with the newest agents-sertraline and paroxetine-had depressionrelated hospitalization costs that were more than 6 times those prescribed fluoxetine [6] . Problems associated with channeling could be reduced considerably by basing treatment cost comparisons on data from a time period during which all SSRIs studied were well-established agents.
The health care cost data used in Sclar et al. [8] are not based on actual costs, but on a notional fixed fee schedule: $50 for each physician and psychiatrist visit, $200 per hospital day, $250 per psychiatric hospital day, and average wholesale price (less rebate, but no dispensing fee) for each 30-day prescription.
To minimize the impact of unobserved disease severity differences, Sclar et al. excluded patients having various psychiatric comorbid conditions, patients switching antidepressants, and patients taking an antidepressant in the 6-month pretreatment period. In addition, patients had to receive three or more consecutive prescriptions for the same antidepressant, which market research data consistently indicate do not reflect the typical patient. To control further for unobserved severity differences, the authors included as regressors in multivariate analyses the number of concomitant nonpsychiatric disease states, total 6-month pretreatment depression-related health care costs, and whether the initial provider was a primary care physician or a psychiatrist. It is worth noting that, while broadly utilized in the literature as methods to control for unobserved severity differences, this control is attained at the cost of additional assumptions, often not verifiable.
Other researchers [7, 26] have critiqued the Sclar et al. [8] research methodology. Excluding patients who switched antidepressants and those who discontinued treatment overlooks important real world phenomena with significant cost implications [1, 7] . Hylan et al. [7] note sample selectivity techniques could have been used which may have reduced the influence of unobserved differences associated with nonrandom sampling. Confining the cost comparisons to depression-related costs omits possible offsets between other medical costs and depression-related costs [26, 27] .
The Hylan et al. Study
Hylan et al. [7] report results from a publicly available retrospective claims database (MarketScan TM ), covering a much wider variety of providers and payers than Sclar et al. The claims are based on actual amounts paid (insurer plus patient copay) rather than notional fee schedules but are again potentially compromised by the channeling phenomenon, since the time period of study included the introduction of paroxetine and sertraline.
Hylan et al. separate total health care costs into mental health and nonmental health, and employ inclusion and exclusion criteria similar to Sclar et al. but include switchers and those who had less than three consecutive antidepressant prescriptions. Based on univariate analyses, they report that mean total health care costs and mean mental health care costs are not significantly different among fluoxetine, sertraline, paroxetine and the TCAs. However, median total and mental health care costs are significantly different: median mental health care costs are highest for fluoxetine and median total health care costs are highest for the TCAs.
Hylan et al. highlight their use of a multivariate two-stage statistical regression procedure that attempts to account for nonrandom treatment choice (sample selectivity). The procedure involves an adjustment for each patient, based on observable characteristics, to control for unobserved differences that might be correlated with the choice of antidepressant and health care expenditures. When this procedure is employed and logarithms of costs are the dependent variable, Hylan et al. find no differences in (log) mental health care costs among the SSRIs, but find significantly lower (log) total health care costs for patients initiating therapy on fluoxetine relative to sertraline. This difference involving sertraline is apparently driven by lower nonmental health care costs among fluoxetine patients. The latter finding contrasts with Sclar et al. [8] who attributed the higher paroxetine and sertraline depression-related health care costs to SSRI titration rate differences. This difference in conclusions and interpretations of sources of costs differences well exemplifies the mixed evidence in the literature.
The application of sample selectivity procedures in the Hylan et al. study is seriously flawed. The selectivity procedure requires initial estimation of a model that characterizes factors affecting nonrandom choice among TCAs and the three SSRIs for each patient from 1990 to 1994. However, Hylan et al. include observations for 1990 and 1991, years when fluoxetine was the only SSRI available, and thus it was impossible for patients/ physicians to have chosen sertraline or, until 1993, paroxetine. This inappropriate incorporation of data from a time period when not all choices were available undermines the attempt to control for sample selectivity, and may help explain why the sample selectivity procedure was statistically significant only for fluoxetine.
It is of course possible that unobserved factors affect SSRI treatment choice in a nonrandom way, and that this sample selectivity affects cost comparisons. Statistical tools have been designed that attempt to overcome the effects of sample selectivity, such as the Heckman [28] procedure or the propensity score method of Rubin [29] . The ability of these tools to control reliably for sample selectivity, as well as the appropriate interpretation of results, remains somewhat controversial [25, [29] [30] [31] [32] [33] [34] . Nonetheless, because sample selectivity could be present and important, in this paper we assess the robustness of least squares findings when the Heckman procedure is employed.
There are a number of other issues that arise not only in the studies cited above, but also in most RACD analyses. Health care expenditure data are typically highly skewed and not normally distributed. A small number of large-cost observations can have a critical impact on the size of the estimated parameters and their statistical significance (overfitting). While logarithmically transforming health care expenditure data can reduce the influence of outlier observations and make traditional statistical assumptions more plausible (e.g., normality of data and homoskedasticity of the random disturbances), the robustness of parame-ter estimates and their statistical inference need to be carefully examined in the context of potentially influential observations [24, [35] [36] [37] . Such robustness checks are not generally reported in RACD studies.
Objectives and Methods
Our objective is to begin to explain and reconcile the mixed SSRI cost comparison evidence by examining the robustness of findings using a variety of alternative methods for dealing with skewed and nonrandom RACD data. We focus on comparing the treatment course, depression-related, and total medical costs associated with patients diagnosed with depression who began treatment with one of the three leading SSRIs in 1995, a time by which all three had become established agents. Since major changes involving the management of treatment for depression and other illnesses have occurred in recent years, use of 1995 to 1996 data is also more likely to reflect the current environment than is the 1989 to 1994 data analyzed in previous studies.
The publicly available fee-for-service MarketScan TM medical claims database from MedStat, including over 600,000 lives, was used to estimate total and depression-related health care costs for 1995 and 1996. This database was also employed by Hylan et al. [7] , but with a 1990 to 1994 time frame for patient selection. Definitions of selection criteria used to obtain records of 2342 patients diagnosed with depression who began treatment with an SSRI in 1995 are described below:
• Variables were defined as follows:
• Antidepressant and Other Prescription Costs: Total receipts to pharmacy ϭ insurer ϩ patient copay, coinsurance and deductibles; • Outpatient Visit Costs: Total payment to providers for outpatient professional services, including laboratory costs, from deductibles, coinsurance, copays, and insurance payments; • Hospitalization Costs: Total payment to hospitals and providers from all sources; • Total Depression-Related Costs: Outpatient, inpatient, and laboratory costs associated with an ICD-9 depression diagnosis code (296.2, 296.3, 300.4, 311) and antidepressant pharmaceutical costs during 12-month treatment period; • Total Health Care Costs: All outpatient, inpatient, laboratory and pharmaceutical costs irrespective of diagnosis, including depressionrelated treatment costs during 12-month treatment period; • Titration: Change in total daily dose from previous prescription by more than Ϯ 5% on same SSRI, for those patients having at least two index SSRI prescriptions; • Index Prescription: First prescription with fluoxetine, paroxetine, or sertraline from January 1 through December 31, 1995 after 6-month antidepressant-free period; • Pretreatment Period: 6-month period prior to date of index (first) SSRI prescription; • Treatment Period: 12-month period following date of index (first) SSRI prescription; • Switching: Change to another SSRI antidepressant from the index SSRI in the 12-month treatment period.
Univariate comparisons of means of categorical variables are based on Cochran-Mantel-Haenszel (CMH) chi-square tests, while those based on continuous variables employ analysis of variance (anova) F -tests. Comparisons of medians are based on the nonparametric Brown-Mood median score test.
Multivariate linear and logistic regression procedures are employed, relating various measures of health care costs (raw and log-transformed cost dependent variables) to a set of explanatory variables. The explanatory variables allow for nonlinear effects on costs, and include patient age (Age) and its square (Agesq), gender (Female), the interaction of age and gender (Age*Female), the number of comorbid medical conditions and its square (Comorbid, Comorbidsq), 6-months preperiod de-pression-related total health expenditures and its square (Precost, Precostsq), 0-1 binary variables for the index prescribing physician (Psyprovider), and the index SSRI (fluoxetine, paroxetine, and sertraline). This equation specification is a nonlinear generalization of that by Sclar et al. [8] . The reference case in these regressions is a male treated by a nonpsychiatrist with fluoxetine. The variables are described in detail below.
Multivariate regressors were defined as follows:
• To determine whether a small number of outlier observations are influential and whether there is possible overfitting [25] , we utilize the Belsley, Kuh, and Welsch (BKW) [35, 36] procedure in which an influential observation is identified by having a studentized residual greater than two in absolute value and an h-hat value Ͼ 2*p/ n , where p is the number of parameters in the model and n is the number of observations in the full sample regression. Since the average value of h-hat over all observations is p/ n , the latter criterion selects observations whose influence on parameter estimates is more than twice the average. The impact of influential observations is then assessed by comparing parameter estimates and inference in the full and trimmed sample regressions, where the latter is the full sample minus the influential observations.
Although use of BKW in many applications can help identify problematic observations, in the current context such observations may well be real and of great concern to managed care officials. In general, trimming on the basis of only studentized residuals will lead to consistent estimates only if the cost data are symmetric, which typically does not occur with health claims data. If the data were log normally distributed, more of the grand mean on the raw scale will be cut from the right tail than the left, leading to biased estimates. Thus we do not prefer trimmed estimates a priori. Rather, we compare full and trimmed sample estimates, and if they yield different inference, we use this as a heurisitic to warn of possible overfitting in the full sample regressions. We implement this robustness check both with the raw scale and logarithmically transformed cost data [24, 37] .
To accommodate possible heteroskedasticity of the disturbances, we employ the White procedure for computing heteroskedasticity-robust standard errors [36] , and also implement the linear version of the White test for homoskedasticity. As another specification check, we evaluate the number of predicted costs that are negative in the nonlog regressions, since least squares estimation of the linear model does not ensure that all predicted values for health care expenditures are positive.
Finally, since health care expenditure data is highly skewed, we rank order the dataset into quartiles, with the first quartile having the lowest and the fourth having the highest health care costs. We then estimate an ordered probit model utilizing maximum likelihood methods, allowing us to determine, e.g., the shift in the probability distribution of being in the lowest or highest quartile when one SSRI is prescribed at index rather than another [36, 38] .
While we have reservations concerning the usefulness and reliability of the two-step sample selectivity method procedure for making cost comparisons, for purposes of sensitivity analyses, we utilize it. Explanatory variables in the first stage multinomial logit SSRI choice equations are similar to those in Hylan et al. and include patient demographics, 0-1 binary variables for having ICD-9 diagnoses DX296.2, DX296.3, DX300.4, DX311 and/or DX309 during the 12-month treatment period, the number of psychotherapy visits in the 6-month preperiod (Visit6), Psyprovider, and whether the patient had a nonpsychiatric hospitalization in the 6-month pretreatment period (Hosp6). The second stage estimations employ the same equation specifications as in the log linear multivariate regressions, but add the inverse Mills ratio (lambda) as a regressor, and employ robust standard error calculations. Identification is attained in part by excluding the diagnosis code, preperiod psychotherapy visits, and preperiod hospitalization variables from the second stage [39] . These excluded variables have been reported to be statistically insignificant predictors of healthcare utilization and costs in other SSRI studies [7, 40] . All computations were performed using the SAS System for Windows, Version 6.12. Table 1 reports patient demographic characteristics at time of index SSRI prescription, and clinical course characteristics during the 12-month treatment period for the 945 fluoxetine, 492 paroxetine, and 905 sertraline individuals meeting study inclusion criteria. There is no significant difference among the SSRI cohorts in age, gender, index provider type, or the number of outpatient visits for depression or all causes. Mean number of antidepressant prescriptions was higher for fluoxetine patients than for paroxetine or sertraline patients ( P ϭ .005 and Ͻ 0.001, respectively). There was notable titration in all cohorts. On average, slightly more than 2% of patients were hospitalized for depression, and approximately 8% were hospitalized for any reason. Table 2 describes health care cost data during the 6-month pretreatment and 12-month treatment period; additional discussion of these data is found in Russell et al. [6] . Mean and median pretreatment period outpatient health care expenditures were similar. Although the sertraline cohort had higher preperiod hospitalization costs, reflecting a higher proportion of sertraline patients hospitalized for depression prior to index SSRI treatment, these differences were not statistically significant. Mean and median outpatient depression-related and total medical costs during the 12-month treatment period are similar across the SSRIs. Depression-related hospitalization costs vary greatly across patients with standard deviations being 7-11 times larger than means. Pharmaceutical costs are significantly higher in the fluoxetine than in the sertraline ( P Ͻ .001) and paroxetine ( P ϭ .016) cohorts. Right tail skewness is substantial in each component, and in total health care costs, with medians being much smaller than means, and measures of skewness being positive and large. However, when either total depression-related or total health care costs are log-transformed, measures of skewness fall close to zero, with slightly negative values in most cases. Statistical test results based on assumed normality of raw scale costs should therefore be interpreted cautiously. Table 3 reports least square estimates of factors affecting 12-month treatment period expenditures for depression related and total health care, in dollars, where the reference case is a male fluoxetine patient treated by a nonpsychiatrist. With this linear specification and raw scale cost data, parameter estimates in the total column are the sum of parameters in the first three columns. Parameter estimates indicate that outpatient and hospitalization depression related health care costs are not different among fluoxetine, paroxetine, and sertraline. While a number of factors significantly affect outpatient expenditures, only pretreatment cost and its square are predictive of hospitalization costs in the treatment period. However, in the antidepressant medication cost equation, when controlling for other factors, pharmaceutical costs n/a n/a n/a Skewness-Total depression-related costs Raw units 9.932 6.982 4.264 n/a n/a n/a Log-transformed Ϫ 0.253 Ϫ 0.261 Ϫ 0.185 n/a n/a n/a Total health care costs- 12 n/a n/a n/a Log-transformed Ϫ0.037 Ϫ0.248 0.004 n/a n/a n/a * P -values for comparisons of means of categorical variables based on CMH chi-square test, and for continuous variables on ANOVA F-test. † Since 97.7% of sample was not hospitalized, median hospitalization cost is equal to 0 and not reported here. Tests for differences in medians are based on the nonparametric Brown-Mood test (SAS procedure NPARIWAY). n/a ϭ not applicable.
Results
are significantly less for paroxetine ($164, P Ͻ .001) and sertraline ($140, P Ͻ .001) when compared to fluoxetine. For total depression-related costs, expenditures are about $239 less for sertraline than fluoxetine ( P Ͻ .01), but there is no significant difference between paroxetine and fluoxetine. When total health care costs are evaluated, there is no significant difference in estimated costs between the fluoxetine, paroxetine, and sertraline cohorts. The adjusted R 2 falls from 0.14 to 0.11 when nondepression related costs are incorporated into the medical care cost measure. Although the linear cost specification does not ensure that all predicted costs are non-negative, this becomes a practical issue only for hospitalizations, where 434 of the 2342 observations (19%) have negative predicted values. Table 4 reports on the sensitivity of the magnitude and significance of the paroxetine and sertraline estimated parameters (relative to fluoxetine) to alternative assumptions and specifications. The top two panels report results with raw scale costs as dependent variable, while the bottom two panels are those with log-transformed costs.
The three important findings initially reported in Table 3 based on raw scale costs are robust to use of heteroskedasticity-consistent standard error calculations and trimmed sample estimations. Specifically, as seen in the top two panels of Table 4 , relative to fluoxetine, antidepressant R x costs are significantly less for paroxetine and sertraline ( P Ͻ .001), total depression-related costs are significantly less for sertraline ( P Ͻ .05), but for total health care costs there is no statistically significant difference among the three SSRIs.
These findings are changed and sharpened considerably when the dependent variable is logtransformed costs. As seen in the bottom two panels of Table 4 , relative to fluoxetine, antidepressant R x costs are about 36% less for paroxetine ( P Ͻ .001) and 30% less for sertraline ( P Ͻ .001). With both trimmed samples and robust standard errors, total depression-related log costs are about 17-18% less for paroxetine than with fluoxetine ( P Ͻ .01 with full sample, P Ͻ .001 with trimmed sample and robust standard errors), and about 20% less for sertraline than fluoxetine ( P Ͻ .001). Moreover, for total health care log costs, there is no statistically significant difference between paroxetine and fluoxetine, but with sertraline these log costs are about 9-10% less than with fluoxetine as the index SSRI ( P Ͻ .01). As documented in the notes to Table 4 , these differential log-costs among SSRIs persist when the regressors precost and its square are log-transformed as well.
To the extent total depression-related and total health care costs exhibit statistically significant differences therefore both Tables 3 and 4 identify antidepressant R x costs as a significant principal driver of these differences. Table 5 describes more detailed evidence regarding the underlying course of treatment and cost consequences of choosing a particular index SSRI. Logistic regression analyses demonstrate that the only significant predictors of being hospitalized for depression are age and the square of pre- treatment costs, not the choice of index SSRI. The probability of being titrated, all else equal, however, is significantly lower for paroxetine than fluoxetine (odds ratio of 0.725, P Ͻ .01), but there is no difference between sertraline and fluoxetine. The odds of being titrated are also higher if the index provider is a psychiatrist (odds ratio 1.447, P Ͻ .001). The probability of a patient ever being given a more costly SSRI prescription having two or more tablets/capsules per day (rather than one per day) is highly associated with choice of index SSRI; the odds ratios relative to fluoxetine are 0.388 for paroxetine (P Ͻ .001) and 0.529 for sertraline (P Ͻ .001). The odds of receiving a multiple tablet daily dose prescription are also higher for patients having greater medical comorbidities (P Ͻ .05) and a psychiatrist as the index provider (odds ratio 1.747, P Ͻ .01). Patients with an index prescription for paroxetine are nearly twice as likely to switch to another SSRI when compared to fluoxetine patients (odds ratio 1.968, P Ͻ .001), while sertraline patients are about a third more likely to switch to another SSRI (odds ratio 1.359, P Ͻ .05).
As an alternative to multivariate linear regressions, Table 6 reports parameter estimates for the ordered probit specification, in which expenditures are ranked by quartile with 1 being the lowest cost quartile and 4 the highest [36] . The significantly negative coefficient estimates indicate that with the exception of outpatient costs, the hospitalization (P Ͻ .001), antidepressant (P Ͻ .001) and total depression-related health care cost (paroxetine P Ͻ .05; sertraline P Ͻ .001) probability distributions are shifted significantly out of the highest quartile 4 and into quartile 3, and from quartile 2 into the lowest cost quartile 1, when paroxetine or sertraline is the index SSRI rather than fluoxetine. Though not reported, qualitatively similar results were found when the cost measure was total health care costs. Table 7 presents results regarding the cost effects of possible nonrandom choice of index SSRI. Entries in the first two columns show that while only a few observed variables significantly affect choice of index prescription, the SSRI choice is in fact nonrandom. Those patients hospitalized with a depression-related diagnosis in the 6-month preperiod were more likely to be prescribed sertraline than fluoxetine at index (P Ͻ .01), while the probability of being prescribed sertraline rather than fluoxetine decreased as the number of preperiod psychotherapy visits increased (P Ͻ .01). Sertraline was less likely to be the index SSRI when a diagnosis was major depressive disorder-recurrent episode (P Ͻ .05). The significant negative intercept term in the paroxetine equation (P Ͻ .01) is consistent with paroxetine being less likely to be the index SSRI than fluoxetine when the patient's diagnosis was major depressive disorder-single episode. The global likelihood ratio test that the odds of choosing any SSRI are even and unaffected by the set of regressors is decisively rejected (P Ͻ .001).
While choice of index SSRI appears to be nonrandom, second stage OLS estimates of the log total medical cost equations indicate that the cost consequences of this are neutral across SSRIs. In particular, none of the second-stage coefficient es- When regressors pre-cost and its square are log-transformed, the paroxetine and sertraline estimates become Ϫ0.06 and Ϫ0.092 in the full sample, and Ϫ0.06 and Ϫ0.102 in the trimmed sample.
timates on lambda (the inverse Mills ratio variable) is significantly different from zero at P Ͻ .05. Similar results (not shown) occur when log depression-related healthcare costs is the dependent variable. Moreover, based on the Chow F-test [36] , with lambda excluded from each SSRI equation, the null hypothesis that all parameters (except intercept terms) are equal across the three SSRI equations is not rejected in the log depression related (F 18,2312 ϭ 1.265, P ϭ .201) and in the log total health care cost specifications (F 18 , 2312 ϭ 1.309, P ϭ .173). These latter results lend strong empirical support for the various logarithmic cost comparison findings reported in the bottom two panels of Table 4 , which incorporate these across SSRI parameter restrictions implicitly.
Discussion
The publicly available data used in this health care cost comparison among the three leading SSRIs are from 1995 and 1996. With these data, we obtain three sets of results that are robust across alternative assumptions, specifications, and procedures. First, as others have, we find substantial unexplained variability in costs, both depressionrelated and total health care, but particularly for hospitalization costs. Second, depression-related outpatient and hospitalization costs are generally unaffected by choice of index SSRI. Depressionrelated antidepressant costs, however, are significantly lower when the index SSRI is sertraline or paroxetine rather than fluoxetine. Total depression-related health care costs are significantly less for sertraline than for fluoxetine (P Ͻ .05 raw units, P Ͻ .001 in log costs), but evidence on whether there is a significant difference in these costs between paroxetine and fluoxetine is mixed (no significance in raw cost units, P Ͻ .01 in log costs). Third, in cases where the most inclusive measure of direct medical costs is used (depression plus nondepression related costs), total medical costs are consistently less when sertraline is the index SSRI rather than fluoxetine, but only in the various log-transformed cost equations is this difference statistically significant (P Ͻ .01); for paroxetine relative to fluoxetine, the difference in total medical costs is never significant. The results reported here differ somewhat from those of Sclar et al. [8] and Hylan et al. [7] , who reported significantly lower total depression-related and lower total health care costs, respectively, when fluoxetine was the index SSRI rather than sertraline or paroxetine. While the Sclar database is not publicly available, in this study we have utilized the same Marketscan database used by Hylan et al. except we have employed more recent 1995 to 1996 data. Although we are unable here to demonstrate it definitively, we believe that since fluoxetine was introduced in January 1988 and sertraline and paroxetine were not introduced until February 1992 and January 1993, the 1990 to 1994 Hylan et al. and the 1989 to 1994 Sclar cost comparisons may be subject to a channeling bias favoring fluoxetine. That physicians have channeled prescriptions for the newer antidepressants to patients not responding satisfactorily to previous treatments, and to those more likely to have complex illnesses, has been documented elsewhere [3, 41] . The potential existence of channeling bias when making statistical efficacy and cost comparisons among drugs was emphasized almost a decade ago [42] , and its impact has also been documented as occurring in therapeutic areas other than antidepressants [43] . The 1995 to 1996 data examined in this study are not as likely to be subject to this channeling bias when comparisons are made among fluoxetine, paroxetine, and sertraline. While our evidence is somewhat mixed regarding the cost consequences of index SSRI choice on total depression-related and total health care costs, a robust finding is that SSRI pharmaceutical acquisition costs are significantly lower for sertraline and paroxetine when compared to fluoxetine. This difference is not explained by simple titration variations, for all else equal, while paroxetine is less likely to be titrated than fluoxetine, no significant difference in titration probabilities is associated with the choice of sertraline versus fluoxetine as the index SSRI.
Two major factors contribute to the higher pharmaceutical costs associated with choice of fluoxetine as the index SSRI. First, sertraline and fluoxetine have equal probabilities of being titrated, but the consequences of titration vary by compound in a critical manner. Whether titration results in a daily dose requiring one, two, three or more tablets/capsules per day depends on the range of dosage strengths offered by the SSRI manufacturer. During the 1995 to 1996 study period, fluoxetine capsules were available in 10 and 20 mg doses, paroxetine tablets in 20 and 30 mg doses, and sertraline tablets in 50 and 100 mg doses. Since the mean final dose in the treatment period was 26.2, 24.9, and 85.2 mg for fluoxetine, paroxetine, and sertraline, respectively, a significant proportion of fluoxetine patients required at least two capsules per day. Logistic regression analyses indicated the probability of a patient being given an SSRI prescription during the 12-month treatment period requiring a daily dosage of two or more tablets/capsules was significantly lower for sertraline and paroxetine than for fluoxetine-odds ratios of 0.529 and 0.388 (P Ͻ .001), respectively.
Second, the cost consequences of this higher multiple-tablet daily regimen for fluoxetine depend on how the various strengths of the compounds are priced. In the 1995 to 1996 US data examined in this study, all three SSRI manufacturers had implemented flat pricing where similar prices were charged for each tablet/capsule, regardless of strength. Mean costs for fluoxetine 10 and 20 mg capsules were $2.00 and $2.02, for paroxetine 20 and 30 mg tablets were $1.76 and $1.78, and for sertraline 50 and 100 mg tablets were $1.86 and $1.91, respectively. The combination of higher multiple-tablet dosing for fluoxetine and flat pricing for all three SSRIs thereby resulted in the observed higher daily medication costs for fluoxetine. We find that in the naturalistic setting utilizing RACD data, choice of index SSRI is nonrandom. We believe SSRI choice is affected by a number of factors, including patient clinical characteristics (i.e., comorbidities, anxiety, lethargy, pharmacokinetic interactions with other medications, etc.), physician experience and knowledge, and length of time an agent has been on the market. In contrast to Hylan et al. [7] , we find that selective, nonrandom SSRI choice is uncorrelated with total depression-related and total health care expenditures. This conclusion may, however, simply reflect the fact that implementation of the Heckman sample selectivity procedure may have corrected for only a subset of patient/physician characteristics, many of which are unobserved and are only imperfectly correlated with observed variables. Our implementation of sample selectivity techniques follows procedures generally followed by others, but the extent to which these techniques control reliably for nonrandom selection remains a matter of some controversy [30] [31] [32] [33] [34] 39] . Although we have implemented a variety of alternative statistical techniques, there may be unobserved or unknown factors that may have affected our findings, and this absence of evidence is not necessarily evidence of absence.
Several other methodological issues are worth noting. Use of the Belsley-Kuh-Welsch [35] procedure for identifying influential observations resulted in a surprisingly small number of such observations being selected-from 0 to 22 in the raw scale cost regressions, and 2-14 in the log-transformed cost equations, less than 1%. It appears therefore that a substantial proportion of observations with studentized residuals greater than two in absolute value had only a roughly average impact on parameter estimates. Since all our principal findings were unaffected by use of the BKW procedure, we interpret this as providing some support for the absence of overfitting in this data, particularly in the log cost specifications, where skewness measures were close to zero.
Regarding robustness to functional form, when the regressor's precost and its square were replaced with their log transforms in the log cost equations, estimates of and inference on the paroxetine and sertraline coefficients were essentially unchanged.
Previous studies have varied in whether they focused on depression-related costs, or total health care costs, or both [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . When making treatment cost comparisons, other things equal, health economists generally prefer using more inclusive measures of costs. It is possible, for example, that reductions in nondepression related costs could offset increases in depression-related costs. This offset phenomenon has been reported in SSRI-TCA cost comparisons [7, 27] . In this study we found no evidence in support of offset differences among the SSRIs. In particular, as can be seen from detailed examination of Table 2 , mean cost differences between fluoxetine and paroxetine, between fluoxetine and sertraline, and between sertraline and paroxetine all steadily increase as one successively compares antidepressant R x costs, total depression-related costs, and total health care costs. The statistical significance of differences, however, does not sharpen as the cost measure becomes more inclusive, for sample standard deviations generally increase proportionally more than means (coefficients of variation rise) as the cost measure is generalized. Although one might therefore expect the power of a test for differences among SSRIs to decline as the cost measure expands, for the log of total health care cost equations we were still able to detect a statistically significant difference between fluoxetine and sertraline (P Ͻ .001), although none was found between fluoxetine and paroxetine. Several other caveats are worth noting. As with other retrospective claims analyses, a limitation of this study is that disease severity and clinical outcomes are unknown. Our cost measures are direct health care costs, and exclude potentially very significant indirect costs and benefits, such as functional impairment and work productivity. Moreover, our direct health care cost measures are societal in that they represent the sum of the patient's actual copay/coinsurance payment plus that by the insurer, to providers. Analyses focused only on direct patient payments, or solely on third party insurer payments, may yield different results.
Our purpose in this study has been to begin to explain and reconcile the mixed SSRI cost comparison evidence in the existing literature. In doing this, we have examined the robustness of findings using alternative procedures employed in other SSRI studies, but with a data set from a common source. It would be useful and informative to implement other and more recently introduced procedures with the same data set. In particular, quantile regression methods, sample selectivity procedures in which the first stage assumption of the independence of irrelevant alternatives is relaxed, alternative retransformation methods, and methods that avoid retransformation entirely, all merit further investigation to assess robustness of findings. Many of these procedures are discussed in Manning and Mullahy (unpublished data, July 1999). 1 Regarding retransformation with heteroskedasticity, however, in the log-cost second stage regressions reported in Table 7 , there was no evidence supporting heteroskedasticity by SSRI, for the root mean squared errors varied by less than 3%-0.762 for fluoxetine, 0.749 for paroxetine, and 0.770 for sertraline. Moreover, though not reported there, P-values on the paroxetine and sertraline coefficients in the White test for homoskedasticity indicated lack of significance (P у 0.48 in depression-related log costs, and у 0.28 in total health care log costs).
Future research might also focus on the extent to which findings from this study can be replicated with other publicly available databases using more recent data, and if findings change materially when the treatment period is expanded from 12 to 24 or 36 months.
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